Twist Bioscience Corp

CRISPR Therapeutics

Recursion Pharmaceuticals

Veracyte

Natera

CareDx

Adaptive Biotechnologies

Guardant Health Inc

Beam Therapeutics

Schrodinger 

ARK Genomic Revolution Multi-Sector ETF

ARKG is an actively managed fund that targets companies involved in the genomics industry.

First Trust Health Care AlphaDEX Fund

iShares Global Healthcare ETF

Vanguard Health Care ETF

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

The best healthcare ETFs patch investors into an area of the market that offers both defensive properties and long-term growth.

Best Healthcare ETFs To Buy Now

ARKG's top holdings were replaced due to poor performance, highlighting the fund's vulnerability to interest rate changes and high concentration in cash-burning companies. ARKG underperformed significantly compared to peers and the Nasdaq, especially during tighter monetary conditions, due to its concentrated portfolio and high valuation multiples. Virtus, with a more diversified and less concentrated portfolio, outperformed ARKG, suggesting that ARKG needs restructuring to better handle interest rate changes.

Interest Rate Regimes And ARKG: Underperformance Explained

Ark Funds pull exclusively from different slivers of the technology sector that also tend to be the most volatile. Economic conditions can make a bigger performance difference over the long term than most investors might expect.

Almost Every Ark Fund Is Now Underperforming The Overall Market. Here's Why.

Invesco DWA Technology Momentum ETF

Strive US Semiconductor ETF

VanEck Vectors Semiconductor ETF

Invesco PHLX Semiconductor ETF

Wall Street roared back after a sell-off early in the month as fears of recession eased. The technology sector, which bore the biggest brunt, rebounded strongly and once again led the market over the past week.

5 Technology ETFs at the Forefront of the August Rebound

iShares U.S. Home Construction ETF

First Trust NASDAQ ABA Community Bank Index Fund

iShares MSCI Global Silver Miners ETF

SPDR S&P Telecom ETF

July witnessed the "Great Rotation" in the U.S. stock market as investors shunned the hot technology stocks in favor of smaller companies and other sectors, which are the bigger beneficiaries of the Fed rate cuts.

5 Sector ETFs That Outperformed With Double-Digit Gains in July

Loncar Cancer Immunotherapy ETF

YieldMax Short TSLA Option Income Strategy ETF

Procure Space ETF

ETRACS Whitney U.S. Critical Technologies Index ETN

Wall Street offered a mixed performance last week.

Best ETFs of Last Week

Genomics is rapidly advancing, shaping our understanding of health, disease, and life itself. Consider investing in the ARK Genomic Revolution ETF for exposure to leading genomics companies. ARKG's active management may not be outperforming compared to passive genomics ETFs like PBE, with potential regulatory and concentration risks.

ARKG: A Genomics Play But Active Isn't Adding Value

TORONTO--(BUSINESS WIRE)---- $ARKG #Cboe--Cboe Canada is pleased to announce BMO has transferred three BMO mutual fund ETF series, trading under the symbols ARKK, ARKW, and ARKG to Cboe Canada.

BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada

ARK Fintech Innovation ETF

ARK Innovation ETF

ARK Industrial Innovation ETF

ARK Web x.0 ETF

Despite touting growth themes in a growth-fueled market, ARK Invest's exchange-traded funds are noticeably trailing major benchmarks. Betting big on a few companies can lead to massively outsize gains or missed opportunities.

Here's How Cathie Wood (Almost) Completely Missed the Boat on Artificial Intelligence (AI) -- and the Simplest Way You Can Avoid Making the Same Mistake

iShares Core U.S. Aggregate Bond ETF

ARK 21Shares Bitcoin ETF

Aberdeen Standard Bloomberg All Commodity Strategy K-1 Free ETF

Abrdn Bloomberg Industrial Metals Strategy K-1 Free ETF

ProShares Bitcoin Strategy ETF

Fidelity Wise Origin Bitcoin Fund

VanEck Bitcoin Trust

iShares Bitcoin Trust

iShares U.S. Pharmaceuticals ETF

Global X Lithium & Battery Tech ETF

AdvisorShares Pure US Cannabis ETF

SPDR S&P 500 ETF Trust

Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.

Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April

ARK Space Exploration & Innovation ETF

There are better ways to approach innovation than the Ark Innovation ETF. The ARK Space Exploration & Innovation ETF is a balanced bet.

3 Cathie Wood ETFs Just Hit 4-Month Lows. Are They Worth Buying Now?

ROBO Global Healthcare Technology and Innovation ETF

iShares U.S. Medical Devices ETF

iShares U.S. Healthcare ETF

Johnson & Johnson

At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.

Time to Tap Healthcare ETFs on Nvidia's AI Ambition?

ARK Genomic Revolution ETF warrants a hold rating due to multiple roadblocks preventing solid returns, including underdeveloped technology, legal hurdles, and unresolved ethical dilemmas. ARKG has a relatively high expense ratio with no dividend yield, and its performance has significantly underperformed the S&P 500 Index. The fund's holdings are concentrated in the healthcare sector, with little overlap with other peer genomics-related funds.

ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons

iShares Nasdaq Biotechnology ETF

Growth-focused investors may wish to set their sights on the hard-hit biotech stocks scene as rates begin to retreat, negative momentum settles and the industry catches a bit of a break for once. Of course, to get a higher chance at outsized gains, one must also have a high risk tolerance and a long-enough investment horizon.

3 Biotech ETFs Overdue for a Bounce

ARK 21Shares Active Bitcoin Ethereum Strategy ETF

ARK Israel Innovative Technology ETF

The 3D Printing ETF

Cathie Wood criticizes the US Federal Reserve for its monetary policy mistakes and argues that deflation, not inflation, should be the concern. Wood presents charts showing that technologically driven deflation has made commodities the cheapest they have been since the 1960s.

Cathie Wood Speaks, ARK Investors Should Listen

Xtrackers Harvest CSI 300 China A-Shares ETF

Amplify Transformational Data Sharing ETF

Calamos CEF Income & Arbitrage ETF

Invesco China Technology ETF

WisdomTree Japan Hedged Equity Fund

iShares China Large-Cap ETF

US Global Jets ETF

KraneShares CSI China Internet ETF

iShares MSCI China ETF

Invesco Golden Dragon China ETF

First Trust NASDAQ Clean Edge Green Energy Index Fund

Invesco Solar ETF

Global X Uranium ETF

Sprott Uranium Miners ETF

United States Oil Fund LP

F/m 10-Year Investment Grade Corporate Bond ETF

F/m 3-Year Investment Grade Corporate Bond ETF

F/m 2-Year Investment Grade Corporate Bond ETF

Hi! This week's ETF Wrap funds looks at China-focused funds that are struggling in 2024, with Clocktower's chief strategist Marko Papic providing his take on concerns tied to the country.

China-focused ETFs struggle amid fears of another regulatory ‘crackdown'

Best Healthcare ETFs to Buy Now

On this episode of the “ETF of the Week” podcast, Tom Lydon discussed the ARK Genomic Revolution ETF (ARKG) with Chuck Jaffe of “Money Life.” The pair talked about several topics regarding the fund to give investors a deeper understanding of the ETF overall.

VIDEO: ETF of the Week: ARK Genomic Revolution ETF (ARKG)

SPDR S&P Regional Banking ETF

Vanguard Real Estate ETF

Vanguard Utilities ETF

The Federal Reserve held its benchmark interest rate steady at a range of 5.25%-5.50% on Dec 13. However, the Fed hinted at three 25-bp rate cuts next year.

Sector ETFs to Gain as Fed Stays Put, Sees Deeper Rate Cuts in 2024

VettaFi's vice chairman Tom Lydon discussed the ARK Genomic Revolution ETF (ARKG) on this week's “ETF of the Week” podcast with Chuck Jaffe of “Money Life.” For more news, information, and analysis, visit VettaFi | ETF Trends.

ETF of the Week: ARK Genomic Revolution ETF (ARKG)

Alerian MLP ETF

Amplify Lithium & Battery Technology ETF

VanEck Vectors Biotech ETF

SPDR Bloomberg 1-3 Month T-Bill ETF

PIMCO Active Bond ETF

Amplify Seymour Cannabis ETF

Global X Autonomous & Electric Vehicles ETF

Alerian Energy Infrastructure ETF

First Trust Global Wind Energy ETF

Global X Genomics & Biotechnology ETF

iShares Core High Dividend ETF

iShares Global Clean Energy ETF

iShares Core S&P Small Cap ETF

iShares Russell 2000 ETF

Adasina Social Justice All Cap Global ETF

KraneShares Electric Vehicles & Future Mobility Index ETF

KraneShares Global Carbon ETF

PIMCO Enhanced Short Maturity Active ETF

Invesco Dynamic Building & Construction ETF

Invesco S&P 500 Equal Weight ETF

Good morning, VettaFi Voices! We are a week out from the VettaFi 2024 Market Outlook Symposium on December 14, which will feature a range of ETF industry leaders discussing their expectations for different areas of the financial markets and the economy in 2024.

VettaFi Voices On: The Outlook for 2024

Caribou Biosciences

Editas Medicine

Robinhood

Eli Lilly

Intellia Therapeutics

Prime Medicine Inc

Regeneron Pharmaceuticals

Verve Therapeutics

Vertex Pharmaceuticals

Genomic medicine is predicted to become a multi-billion-dollar industry. Even so, this market will probably take years to mature, and risks abound as a result.

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

Cathie Wood is known for investing in cutting-edge innovators. Her ARK Genomic Revolution ETF owns several gene-editing companies, but Prime Medicine might be the best of the bunch.

1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years

ARK Genomic Revolution ETF focuses on genomic innovation in sectors such as healthcare, information technology, and energy. The fund's buying and selling activity gives us clues about the degrees of conviction relative to its main holdings. The fund has engaged in significant buying and selling activity, with a focus on stocks such as Recursion, Pacific Biosciences and Exact Sciences.

Analyzing ARKG's Trading Activity In Q3

Some of the best gene editing stocks could soon see a massive boost. In just days, the U.S. FDA could approve the first gene-editing treatment of sickle cell disease (SCD) from CRISPR Therapeutics (NASDAQ: CRSP ), a move that could set off a firestorm of interest in all things gene editing.

The 3 Best Gene Editing Stocks on the Frontier of Medicine

News for ARK Genomic Revolution Multi-Sector ETF ETF (ARKG)